FDA Guidance on Developing Drugs for Clostridioides difficile Infection
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is finalizing guidance for companies developing drugs to treat, reduce recurrence, or prevent Clostridioides difficile infection. It gives drug sponsors the agency’s current expectations for clinical development, including efficacy and nonclinical assessment considerations. The guidance affects pharmaceutical and biotech companies working on CDI therapies, as well as clinical trial teams and regulatory affairs staff. It is not legally binding, but companies seeking FDA approval will likely use it to design studies and prepare submissions.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Finalizes FDA guidance for drug development targeting treatment, recurrence reduction, or prevention of CDI
- Updates and clarifies expectations for efficacy and nonclinical assessments
- Confirms that the guidance reflects FDA’s current thinking but is not legally binding
Obligations
What this law requires
Any comment submission to FDA on this guidance must include Docket No. FDA-2022-D-1261 and identify the guidance as "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention."
Electronic comments submitted through Regulations.gov must not include confidential information that the submitter does not want publicly posted, because electronic comments and attachments will be posted unchanged to the public docket.
A submitter that wants FDA to consider confidential information without public disclosure must submit the comment only as a written/paper submission, not as an electronic submission.
A confidential written/paper comment submission must include two copies: one complete copy labeled with a heading or cover note stating "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION" and one redacted copy with the claimed confidential information blacked out for public posting.
If a submitter does not want their name or contact information made publicly available, they must provide that information on the cover sheet rather than in the body of the comment and must identify it as confidential.